Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.

Wischik, C.M., et al. (2014) Tau-aggregation inhibitor therapy for Alzheimer's disease. Available at Biochemical Pharmacology

Wischik, C.M., et al. (2014) TauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX. Presented at 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy.